PRE-TEST QUESTIONNAIRE
Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)
Saturday, September 20th, 2025 | Huntington Beach, CA
Name
*
First Name
Last Name
Email
*
example@example.com
1. Which of the following statements is false?
*
a. The Classic dose-response where clinical effectiveness increases with dose is not always seen in lupus with immune modulating treatments
b. Myeloid Cells are important in regulating B Cell survival and differentiation through secretion of BLys (BAFF)
c. CAR T-cell therapy avoids the problems seen with Rituximab that may be caused by increased BLyS
d. Longterm drug-free remission for up to a year or more has occurred in some SLE patients receiving CAR T-cell therapy
2. An advantage of CAR T-cell treatment in systemic lupus erythematosus (SLE) is:
*
a. Once the complex administrative process is completed, many patients may reduce or stop other immune modulating treatments and remain well for many months or more
b. It puts all patients with lupus into remission regardless of their individual pathology
c. There is no risk for neurologic side effects in SLE
d. It is relatively inexpensive compared to the use of these agents in cancer
3. A major disadvantage of autologous CAR T-cell treatment in SLE is:
*
a. A high incidence of ICANS (Immune Cell Associated Neurotoxicity Syndrome)
b. Delays in treatment due to the process needed to manufacture the cells
c. A high incidence of high-grade CRS (cytokine release syndrome)
d. It is effective in only a small minority of patients
Thank you! Please press submit to enter your information.
Submit
Should be Empty: